Test Price
1,500 AED✅ Home Collection Available
Monoclonal Gammopathy of Undetermined Significance (MGUS) Panel – Accurate Screening & Diagnosis in Dubai, UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Complimentary Telephonic Post-Test Guidance with a DHA-licensed physician.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The MGUS Panel is a specialized electrophoretic and immunochemical assay designed to detect, quantify, and characterize monoclonal immunoglobulins in serum. This panel is crucial for distinguishing benign MGUS from malignant plasma cell disorders such as multiple myeloma or AL amyloidosis. Our laboratory employs capillary electrophoresis combined with immunofixation and nephelometry, with reflex LC-MS/MS for ambiguous bands, ensuring unparalleled diagnostic sensitivity.
| Feature | Our MGUS Panel (ISO 9001:2015 Lab) | Closest Alternative Routine Labs |
|---|---|---|
| Methodology | Capillary Electrophoresis + Immunofixation + Nephelometry; Reflex LC-MS/MS for ambiguous bands | Agarose Gel Electrophoresis only |
| Reporting Speed | Next-day report (sample by 9 AM) | 3–5 working days |
| Clinical Support | DHA-licensed specialist tele-consultation included | None |
| Sensitivity | 99.9% (detects faint bands & small clones) | Variable; risk of missing small M-proteins |
Physician Insight & Safety Protocols
Mr. Prabhakar Reddy Kalathoor | Specialist Diagnostic Radiology | DHA Registration ID: 61713011
"As a DHA-licensed Specialist Diagnostic Radiology, I emphasize that an abnormal MGUS panel result requires careful clinical correlation with serum free light chains, bone marrow studies, and imaging. Patients should never self-interpret laboratory data; consult a specialist to evaluate individual progression risk. Regular monitoring is vital because approximately 1% of MGUS cases per year transform into multiple myeloma or related malignancy."
Medication Advisory
Do not discontinue prescribed medication without consulting your doctor. Never alter your therapy based on test results alone. Always discuss your findings with a DHA-licensed physician before making any changes.
Exclusion Criteria & Emergency Red Flags
- Specimen Rejection: Grossly hemolyzed samples are unacceptable; repeat collection will be advised.
- Therapeutic Interference: Patients receiving therapeutic monoclonal antibodies (e.g., daratumumab) may require specialist evaluation to avoid assay interference.
- Not for Emergency Diagnosis: This panel alone does not confirm malignancy; it must be interpreted alongside clinical evaluation.
- Seek immediate emergency care if you experience: sudden severe bone pain, unexplained fractures, extreme fatigue, signs of hypercalcemia (nausea, confusion, frequent urination), or rapidly worsening kidney function — these may herald multiple myeloma progression.
Patient FAQ & Clinical Guidance
1. What is the difference between MGUS and Multiple Myeloma?
MGUS is a benign precursor condition where monoclonal proteins are present without end-organ damage or CRAB criteria. Multiple myeloma develops when these plasma cells become malignant, causing bone lesions, anemia, renal failure, and hypercalcemia. Regular monitoring helps detect transformation early.
2. Why is this panel required for kidney disease evaluation?
Monoclonal free light chains can deposit in kidneys causing damage; this panel detects harmful proteins to protect renal function. Nephrologists order the MGUS panel when kidney biopsies show light-chain deposition disease or unexplained proteinuria. Early detection guides therapy and may prevent dialysis.
3. Are there any risks or special preparations for the blood draw?
No special preparation is needed; a standard venous blood sample is collected via our VIP home service. Our phlebotomists follow ISO cold-chain protocols, and the procedure is virtually painless. Results remain accurate even if you are on regular medications; never stop prescribed drugs.
UAE Regulatory & Data Privacy Adherence
All services adhere to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent are guided by Federal Decree-Law No. 4 of 2016 on Medical Liability. The laboratory operates under DHA Facility License Number 1143 and is located at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. Corporate branding: DNA Labs UAE.
Clinical & Logistical Metadata
| Test Name | Monoclonal Gammopathy of Undetermined Significance (MGUS) Panel |
| Price (AED) | 1,500 AED |
| Turnaround Time | Next-day report (sample received by 9 AM) |
| Sample Type / Matrix | Serum (peripheral blood) |
| Methodology Used | Capillary Electrophoresis, Immunofixation, Nephelometry, Reflex LC-MS/MS |
| ICD-10-CM Code | D47.2 (Monoclonal gammopathy of undetermined significance) |
| LOINC Code | 24558-5 (Monoclonal gammopathy panel) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians